### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

#### VERTEX PHARMACEUTICALS INC / MA

Form 4

August 01, 2011

# FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

OMB Number: 3235-0287

Expires: January 31, 2005

0.5

Estimated average burden hours per response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may continue. *See* Instruction

Check this box

if no longer

Section 16.

Form 4 or

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person <u>\*</u> Kelly Lisa

2. Issuer Name **and** Ticker or Trading Symbol

Issuer

VERTEX PHARMACEUTICALS

INC / MA [VRTX]

(Check all applicable)

Director \_\_\_\_\_ 10% Owner

5. Relationship of Reporting Person(s) to

3. Date of Earliest Transaction

(Month/Day/Year) 07/29/2011

\_X\_ Officer (give title \_\_\_\_ Other (specify below) SVP, Human Resources

C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY

(Street)

(State)

(First)

(Middle)

(Zip)

SI

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person \_\_\_\_ Form filed by More than One Reporting

Person

ativa Casumitias Assuim

CAMBRIDGE, MA 02139

| (City)                               | (State)                                 | Table   | e I - Non-D                            | erivative   | Secur            | ities Acqu   | ured, Disposed of  | , or Beneficial                                       | ly Owned |
|--------------------------------------|---|---|--|---|------------------|--|--|---|----------|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transactio<br>Code<br>(Instr. 8) | 4. Securities Acquired (n(A) or Disposed of (D) (Instr. 3, 4 and 5) |                  | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |          |
|                                      |   |   | Code V                                 | Amount  | (A)<br>or<br>(D) | Price  | Reported<br>Transaction(s)<br>(Instr. 3 and 4)                       |   |          |
| Common<br>Stock                      | 07/29/2011                              |   | M                                      | 954   | A                | \$<br>28.84  | 39,036   | D   |          |
| Common<br>Stock                      | 07/29/2011                              |   | S <u>(1)</u>                           | 954   | D                | \$ 52.5  | 38,082   | D   |          |
| Common<br>Stock                      |   |   |  |   |                  |  | 1,520  | I   | 401(k)   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) |         | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |  | 8. Pr<br>Deri<br>Secu<br>(Inst |
|---|---|--------------------------------------|--|---------|--|--------------------|---|--|--------------------------------|
|   |   |                                      | Code V                                 | (A) (D) | Date<br>Exercisable                                      | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |                                |
| Stock<br>Option                                     | \$ 28.84  | 07/29/2011                           | M                                      | 954     | (2)  | 07/12/2021         | Common<br>Stock   | 954                                    | 9                              |

## **Reporting Owners**

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Kelly Lisa C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE, MA 02139

SVP, Human Resources

## **Signatures**

Kenneth S. Boger, Attorney-In-Fact

08/01/2011

Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
- (2) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2